The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1745
January 5, 2026
View Complete Issue         Table of Contents 2019 
Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria
January 5, 2026 (Issue: 1745)
The FDA has approved remibrutinib (Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H1-antihistamine treatment. Remibrutinib is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria
Article code: 1745b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.